| Drug Name |
Levalbuterol |
| Drug ID |
BADD_D01262 |
| Description |
Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
[Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol). |
| Indications and Usage |
Indicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB13139
|
| KEGG ID |
D08124
|
| MeSH ID |
D064412
|
| PubChem ID |
123600
|
| TTD Drug ID |
D02ZJI
|
| NDC Product Code |
0378-9691; 0093-4147; 65862-943; 0378-9692; 63187-953; 0378-9690; 65862-944; 0093-4146; 65862-945; 0093-4145; 0378-6993; 65862-942; 0093-4148 |
| UNII |
EDN2NBH5SS
|
| Synonyms |
Levalbuterol | Xopenex | Levalbuterol Hydrochloride | Hydrochloride, Levalbuterol | Levosalbutamol Hydrochloride | Hydrochloride, Levosalbutamol |
